|
1
|
Zhou L, Shi H, Jiang S, Ruan C and Liu H:
Deep molecular response by IFN-α and dasatinib combination in a
patient with T315I-mutated chronic myeloid leukemia.
Pharmacogenomics. 17:1159–1163. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chaudhary AK, Chaudhary S, Ghosh K,
Shanmukaiah C and Nadkarni AH: Secretion and expression of matrix
metalloproteinase-2 and 9 from bone marrow mononuclear cells in
myelodysplastic syndrome and acute myeloid leukemia. Asian Pac J
Cancer Prev. 17:1519–1529. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Janowska-Wieczorek A, Majka M,
Marquez-Curtis L, Wertheim JA, Turner AR and Ratajczak MZ:
Bcr-abl-positive cells secrete angiogenic factors including matrix
metalloproteinases and stimulate angiogenesis in vivo in Matrigel
implants. Leukemia. 16:1160–1166. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Di Stefano C, Mirone G, Perna S and Marfe
G: The roles of microRNAs in the pathogenesis and drug resistance
of chronic myelogenous leukemia (Review). Oncol Rep. 35:614–624.
2016.PubMed/NCBI
|
|
5
|
Hershkovitz-Rokah O, Modai S,
Pasmanik-Chor M, Toren A, Shomron N, Raanani P, Shpilberg O and
Granot G: Restoration of miR-424 suppresses BCR-ABL activity and
sensitizes CML cells to imatinib treatment. Cancer Lett.
360:245–256. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang WZ, Pu QH, Lin XH, Liu MY, Wu LR, Wu
QQ, Chen YH, Liao FF, Zhu JY and Jin XB: Silencing of miR-21
sensitizes CML CD34+ stem/progenitor cells to
imatinib-induced apoptosis by blocking PI3K/AKT pathway. Leuk Res.
39:1117–1124. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kreisel SH, Stroick M, Griebe M, Alonso A,
Reuter B, Hennerici MG and Fatar M: True effects or bias? MMP-2 and
MMP-9 serum concentrations after acute stroke. Cerebrovasc Dis.
42:352–360. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu YJ, Neoh CA, Tsao CY, Su JH and Li HH:
Sinulariolide suppresses human hepatocellular carcinoma cell
migration and invasion by inhibiting matrix metalloproteinase-2/−9
through MAPKs and PI3K/Akt signaling pathways. Int J Mol Sci.
16:16469–16482. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ries C, Loher F, Zang C, Ismair MG and
Petrides PE: Matrix metalloproteinase production by bone marrow
mononuclear cells from normal individuals and patients with acute
and chronic myeloid leukemia or myelodysplastic syndromes. Clin
Cancer Res. 5:1115–1124. 1999.PubMed/NCBI
|
|
10
|
Golubnitschaja O, Yeghiazaryan K, Stricker
H, Trog D, Schild HH and Berliner L: Patients with hepatic breast
cancer metastases demonstrate highly specific profiles of matrix
metalloproteinases MMP-2 and MMP-9 after SIRT treatment as compared
to other primary and secondary liver tumours. BMC Cancer.
16:3572016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen CC, Liu TY, Huang SP, Ho CT and Huang
TC: Differentiation and apoptosis induction by lovastatin and
γ-tocotrienol in HL-60 cells via Ras/ERK/NF-κB and Ras/Akt/NF-κB
signaling dependent down-regulation of glyoxalase 1 and HMG-CoA
reductase. Cell Signal. 27:2182–2190. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu J, Wang Y, Liu RH and He X: Novel
triterpenoids isolated from raisins exert potent antiproliferative
activities by targeting mitochondrial and Ras/Raf/ERK signaling in
human breast cancer cells. Food Funct. 7:3244–3251. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chien CM, Lin KL, Su JC, Chuang PW, Tseng
CH, Chen YL, Chang LS and Lin SR: Naphtho[1,2-b]furan-4,5-dione
induces apoptosis of oral squamous cell carcinoma: Involvement of
EGF receptor/PI3K/Akt signaling pathway. Eur J Pharmacol.
636:52–58. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li Q, Huai L, Zhang C, Wang C, Jia Y, Chen
Y, Yu P, Wang H, Rao Q, Wang M, et al: Icaritin induces AML cell
apoptosis via the MAPK/ERK and PI3K/AKT signaling pathways. Int J
Hematol. 97:617–623. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zeng D, Wang J, Kong P, Chang C and Li J
and Li J: Ginsenoside Rg3 inhibits HIF-1α and VEGF expression in
patient with acute leukemia via inhibiting the activation of
PI3K/Akt and ERK1/2 pathways. Int J Clin Exp Pathol. 7:2172–2178.
2014.PubMed/NCBI
|
|
16
|
Yi YW, Hong W, Kang HJ, Kim HJ, Zhao W,
Wang A, Seong YS and Bae I: Inhibition of the PI3K/AKT pathway
potentiates cytotoxicity of EGFR kinase inhibitors in
triple-negative breast cancer cells. J Cell Mol Med. 17:648–656.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Becker H, Suciu S, Rüter BH, Platzbecker
U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Muus
P, et al: Decitabine versus best supportive care in older patients
with refractory anemia with excess blasts in transformation (RAEBt)
- results of a subgroup analysis of the randomized phase III study
06011 of the EORTC Leukemia Cooperative Group and German MDS Study
Group (GMDSSG). Ann Hematol. 94:2003–2013. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sakurai M, Mori T, Karigane D, Tozawa K,
Matsuki E, Shimizu T, Yokoyama K, Nakajima H, Kanda Y and Okamoto
S: Unfavorable outcome of chronic myelogenous leukemia in
adolescent and young adults treated with tyrosine kinase
inhibitors. Int J Hematol. 102:342–348. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Iriyama N, Fujisawa S, Yoshida C, Wakita
H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi
K, et al: Shorter halving time of BCR-ABL1 transcripts is a novel
predictor for achievement of molecular responses in newly diagnosed
chronic-phase chronic myeloid leukemia treated with dasatinib:
Results of the D-first study of Kanto CML study group. Am J
Hematol. 90:282–287. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yue X, Cao D, Lan F, Pan Q, Xia T and Yu
H: MiR-301a is activated by the Wnt/β-catenin pathway and promotes
glioma cell invasion by suppressing SEPT7. Neuro-oncol.
18:1288–1296. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bhutra S, Lenkala D, LaCroix B, Ye M and
Huang RS: Identifying and validating a combined mRNA and microRNA
signature in response to imatinib treatment in a chronic myeloid
leukemia cell line. PLoS One. 9:e1150032014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Valleron W, Laprevotte E, Gautier EF,
Quelen C, Demur C, Delabesse E, Agirre X, Prósper F, Kiss T and
Brousset P: Specific small nucleolar RNA expression profiles in
acute leukemia. Leukemia. 26:2052–2060. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Song JH, Kim SH, Cho D, Lee IK, Kim HJ and
Kim TS: Enhanced invasiveness of drug-resistant acute myeloid
leukemia cells through increased expression of matrix
metalloproteinase-2. Int J Cancer. 125:1074–1081. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Aref S, Osman E, Mansy S, Omer N, Azmy E,
Goda T and El-Sherbiny M: Prognostic relevance of circulating
matrix metalloproteinase-2 in acute myeloid leukaemia patients.
Hematol Oncol. 25:121–126. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liang B, Yin JJ and Zhan XR: MiR-301a
promotes cell proliferation by directly targeting TIMP2 in multiple
myeloma. Int J Clin Exp Pathol. 8:9168–9174. 2015.PubMed/NCBI
|
|
26
|
Wang H, Jia XH, Chen JR, Wang JY and Li
YJ: Osthole shows the potential to overcome P-glycoprotein-mediated
multidrug resistance in human myelogenous leukemia K562/ADM cells
by inhibiting the PI3K/Akt signaling pathway. Oncol Rep.
35:3659–3668. 2016.PubMed/NCBI
|
|
27
|
Zhang X, Dong W, Zhou H, Li H, Wang N,
Miao X and Jia L: α-2,8-sialyltransferase is involved in the
development of multidrug resistance via PI3K/Akt pathway in human
chronic myeloid leukemia. IUBMB Life. 67:77–87. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rahmani M, Aust MM, Attkisson E, Williams
DC Jr, Ferreira-Gonzalez A and Grant S: Dual inhibition of Bcl-2
and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in
human myeloid leukemia cells through a GSK3- and Bim-dependent
mechanism. Cancer Res. 73:1340–1351. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen C, Chang YC, Lan MS and Breslin M:
Leptin stimulates ovarian cancer cell growth and inhibits apoptosis
by increasing cyclin D1 and Mcl-1 expression via the activation of
the MEK/ERK1/2 and PI3K/Akt signaling pathways. Int J Oncol.
42:1113–1119. 2013.PubMed/NCBI
|
|
30
|
Guo Y, Li Y, Shan Q, He G, Lin J and Gong
Y: Curcumin potentiates the anti-leukemia effects of imatinib by
downregulation of the AKT/mTOR pathway and BCR/ABL gene expression
in Ph+ acute lymphoblastic leukemia. Int J Biochem Cell
Biol. 65:1–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
